PMID- 10708923
OWN - NLM
STAT- MEDLINE
DCOM- 20000509
LR  - 20190826
IS  - 0165-1781 (Print)
IS  - 0165-1781 (Linking)
VI  - 98
IP  - 1
DP  - 2000 Feb 28
TI  - Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood 
      flow: a co-registered SPECT and MRI study.
PG  - 15-28
AB  - 3,4-methylenedioxymethamphetamine (MDMA), an illicit recreational drug, damages 
      serotonergic nerve endings. Since the cerebrovasculature is regulated partly by 
      the serotonergic system, MDMA may affect cerebral blood flow (CBF) in humans. We 
      evaluated 21 abstinent recreational MDMA users and 21 age- and gender-matched 
      healthy subjects with brain SPECT and MRI. Ten of the MDMA subjects also had 
      repeat SPECT and MRI after receiving two doses of MDMA. Abstinent MDMA users 
      showed no significantly different global or regional CBF (rCBF) compared to the 
      control subjects. However, within 3 weeks after MDMA administration, rCBF 
      remained decreased in the visual cortex, the caudate, the superior parietal and 
      dorsolateral frontal regions compared to baseline rCBF. The decreased rCBF tended 
      to be more pronounced in subjects who received the higher dosage of MDMA. Two 
      subjects who were scanned at 2-3 months after MDMA administration showed 
      increased rather than decreased rCBF. Low-dose recreational MDMA use does not 
      cause detectable persistent rCBF changes in humans. The lack of long-term rCBF 
      changes may be due to a non-significant effect of serotonergic deficits on rCBF, 
      or regeneration of serotonergic nerve terminals. The subacute decrease in rCBF 
      after MDMA administration may be due to the direct effect of MDMA on the 
      serotonergic system or the indirect effects of its metabolites on the 
      dopaminergic system; the preliminary data suggest these effects may be transient.
FAU - Chang, L
AU  - Chang L
AD  - Department of Neurology, UCLA School of Medicine, Harbor-UCLA Medical Center, 
      1000 W. Carson Street, B-4, Torrance, CA 90509, USA. linda_chang@humc.edu
FAU - Grob, C S
AU  - Grob CS
FAU - Ernst, T
AU  - Ernst T
FAU - Itti, L
AU  - Itti L
FAU - Mishkin, F S
AU  - Mishkin FS
FAU - Jose-Melchor, R
AU  - Jose-Melchor R
FAU - Poland, R E
AU  - Poland RE
LA  - eng
GR  - DA00280/DA/NIDA NIH HHS/United States
GR  - MH00534/MH/NIMH NIH HHS/United States
GR  - MO1 RR00425/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Serotonin Agents)
RN  - 3B744AG22N (Technetium Tc 99m Exametazime)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Brain/diagnostic imaging/*drug effects/pathology
MH  - Case-Control Studies
MH  - Cerebrovascular Circulation/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage/*adverse effects
MH  - Radiopharmaceuticals
MH  - Serotonin Agents/administration & dosage/*adverse effects
MH  - Technetium Tc 99m Exametazime
MH  - Time Factors
MH  - *Tomography, Emission-Computed, Single-Photon
EDAT- 2000/03/10 09:00
MHDA- 2000/05/16 09:00
CRDT- 2000/03/10 09:00
PHST- 2000/03/10 09:00 [pubmed]
PHST- 2000/05/16 09:00 [medline]
PHST- 2000/03/10 09:00 [entrez]
AID - S0925492799000487 [pii]
AID - 10.1016/s0925-4927(99)00048-7 [doi]
PST - ppublish
SO  - Psychiatry Res. 2000 Feb 28;98(1):15-28. doi: 10.1016/s0925-4927(99)00048-7.